Skip to main content

Advances in Drug Delivery Strategies for Microbial Healthcare Products

  • Chapter
  • First Online:
Book cover Pharmaceuticals from Microbes

Part of the book series: Environmental Chemistry for a Sustainable World ((ECSW,volume 26))

Abstract

Biomacromolecules produced by microorganisms have been employed in healthcare ever since ancient times as part of fermented products or natural remedies, but from the discovery of penicillin in 1928 by Alexander Fleming, it is impossible to conceive medicine without microbial products. In addition to antibiotics, microorganisms produce secondary metabolites currently employed as anti-inflammatory, immunosuppressant, and antitumoral drugs, among others. As with any other well-established drugs, undesirable side effects may occur with these compounds due to excessive systemic drug concentrations, and their pharmacological activity can be lost by the development of resistance in the target cells. Besides, many microbial drugs have intrinsic physicochemical properties that limit their application in healthcare such as low aqueous solubility, low bioavailability, acute toxicity, and fast systemic and pre-systemic degradation.

Here we review the critical aspects of innovative strategies for microbial products of high interest for academia and healthcare industry. In order to improve some of the current drug limitations, researchers have explored multiple advanced formulation approaches based on disruptive technologies. By means of new biomaterials and nanotechnology, it is possible to maximize the possibilities for functionalization and interfacing with the biological environment, a characteristic that leads to unique properties as drug delivery carriers. These approaches have resulted in improved pharmacological effects and pharmaceutical characteristics as compared to classical formulations, representing the dawn of a new era in microbial healthcare products.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

FDA:

Food and Drug Administration

GRAS:

generally recognized as safe

MRSA:

methicillin-resistant S. aureus

PEG:

poly(ethylene glycol)

PEGylated:

functionalized with PEG

PLGA :

poly(lactic-co-glycolic acid)

TAT peptide:

transactivator of transcription of human immunodeficiency virus (HIV1)

VRE:

vancomycin-resistant enterococci

VRSA:

vancomycin-resistant S. aureus

References

Download references

Acknowledgment

This work was supported by Fundación BBVA, Proyectos de Investigación en Biomedicina (2014-PO0110), and Ministerio de Economía y Competitividad (SAF2014-58189-R, FEDER Funds).

The chemical structures were obtained from the PubChem Database (https://pubchem.ncbi.nlm.nih.gov/) and represented using the MarvinSketch software (ChemAxon Ltd, Budapest, Hungary).

Protein molecular models were obtained from the Protein Data Bank (PDB; http://www.rcsb.org/pdb; 1WCO). Molecular graphics and analyses were performed with the UCSF Chimera package (Pettersen et al. 2004). Chimera is developed by the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco (supported by NIGMS P41-GM103311).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jose Manuel Ageitos .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Ageitos, J.M., Garcia-Fuentes, M. (2019). Advances in Drug Delivery Strategies for Microbial Healthcare Products. In: Arora, D., Sharma, C., Jaglan, S., Lichtfouse, E. (eds) Pharmaceuticals from Microbes. Environmental Chemistry for a Sustainable World, vol 26. Springer, Cham. https://doi.org/10.1007/978-3-030-01881-8_1

Download citation

Publish with us

Policies and ethics